Cystic Fibrosis Centre, Department of Paediatrics, Jena University Hospital, Friedrich-Schiller-University, Am Klinikum 1, 07747, Jena, Germany.
Institute of Medical Microbiology, Jena University Hospital, Friedrich-Schiller-University, Jena, Germany.
BMC Pulm Med. 2022 Mar 24;22(1):101. doi: 10.1186/s12890-022-01900-8.
In Germany, the first case of coronavirus disease 2019 (COVID-19) was registered on 28 January 2020. By February 2021, the third wave of the pandemic began. So far, only few data are available on the SARS-CoV-2 prevalence and the clinical impact of an infection in patients with cystic fibrosis (CF).
From February 2020 until March 2021, we screened 156 CF patients for anti-SARS-CoV-2 IgG antibodies (serology) and the presence of SARS-CoV-2 in deep throat saliva or nasopharyngeal swabs (molecular testing). From patients with confirmed SARS-CoV-2 infection, we recorded symptoms and collected clinical data.
In total, 13 patients (8.3%) were tested positive for SARS-CoV-2 infection, most of them during the second and the beginning third wave of the pandemic. Ten positive tested patients described symptoms linked to COVID-19. The most common symptom was cough followed by fatigue and headache. SARS-CoV-2 infection did not impair lung function. No positive tested patient needed to be hospitalized.
SARS-CoV-2 infections in patients with CF are not as rare as initially anticipated, as frequent testing revealed. However, infected patients did not experience more severe clinical courses or worse clinical outcome. Our observation is in line with published reports indicating that individuals with CF are not at higher risk for severe COVID-19.
2020 年 1 月 28 日，德国出现首例 2019 年冠状病毒病（COVID-19）病例。到 2021 年 2 月，大流行开始了第三波。到目前为止，关于囊性纤维化（CF）患者中 SARS-CoV-2 的流行情况以及感染的临床影响，仅有少数数据。
从 2020 年 2 月到 2021 年 3 月，我们对 156 名 CF 患者进行了抗 SARS-CoV-2 IgG 抗体（血清学）和深喉唾液或鼻咽拭子中 SARS-CoV-2 的存在（分子检测）筛查。对确诊 SARS-CoV-2 感染的患者，我们记录了症状并收集了临床数据。
总共有 13 名患者（8.3%）检测出 SARS-CoV-2 感染呈阳性，其中大多数在第二波和第三波大流行开始时感染。10 名检测呈阳性的患者描述了与 COVID-19 相关的症状。最常见的症状是咳嗽，其次是疲劳和头痛。SARS-CoV-2 感染没有损害肺功能。没有检测呈阳性的患者需要住院治疗。
如频繁检测所显示的，CF 患者的 SARS-CoV-2 感染并不像最初预期的那样罕见。然而，感染患者并未经历更严重的临床病程或更差的临床结局。我们的观察结果与已发表的报告一致，表明 CF 患者患严重 COVID-19 的风险没有增加。
